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El papel de los anticuerpos de la enfermedad celíaca en el seguimiento del paciente con una dieta sin gluten 
Background: The detection of autoantibodies directed 
against tissue transglutaminase have a well-established 
role in the diagnosis of celiac disease and in long term 
follow up.
Aim of study:
1. To determine the role of celiac disease antibodies, in 
follow up the response of the patient with CD while 
he is on GFD.
2. To study the difference in the response between pa-
tients with GIT and non-GIT manifestations.
Patient and method: across sectional study was con-
ducted from 1st of Feb. 2015 to 1st of May 2016,123 pa-
tients were involved in this study, and includes all patients 
that consult the outpatient clinic in maternity and Chil-
dren Hospital in AL-Diwaniah Governorate, complaining 
of chronic diarrhea or failure to thrive, patients with pica 
or anemia without clear cause, patient with short stature 
without obvious pathology, and celiac patients who diag-
nosed previously, their age between 9 month to 12 years. 
From each patient, five ml of venous blood aspirated and 
sent to the lab where Enzyme Linking Immunosorbant as-
say (ELISA), measurement of auto antibodies specific for 
celiac disease (anti-endomysial IgA, IgG and anti-tissue 
transglutaminase IgA, IgG) was done.  
Result: there was significant decrease in all enzymes level 
after several months of gluten free diet.
Conclusion: Celiac disease can present with variable 
manifestations, the follow up of celiac pt. may be impor-
tant to detect the adherence of the pt.to gluten free diet. 
Keywords: autoantibodies, dietetic changes, Celiac Dis-
ease, enzymes level
Antecedentes: la detección de autoanticuerpos dirigidos 
contra la transglutaminasa tisular tiene un papel bien es-
tablecido en el diagnóstico de la enfermedad celíaca y en 
el seguimiento a largo plazo.
Objetivo de estudio:
1. Para determinar el papel de los anticuerpos de la enfer-
medad celíaca, en el seguimiento de la respuesta del 
paciente con EC mientras está en GFD.
2. Estudiar la diferencia en la respuesta entre pa-
cientes con GIT y manifestaciones no GIT. 
Paciente y método: se realizó un estudio transversal 
desde el 1 de febrero de 2015 hasta el 1 de mayo de 
2016. Participaron en este estudio 1223 pacientes, e 
incluye a todos los pacientes que consultan a la clíni-
ca ambulatoria de maternidad y al Hospital de Niños 
de la Gobernación de AL-Diwaniah, quejándose. De 
diarrea crónica o falta de crecimiento, pacientes con 
pica o anemia sin causa clara, pacientes con baja es-
tatura sin patología evidente y pacientes celíacos que 
diagnosticaron previamente su edad entre 9 meses y 
12 años. De cada paciente, se aspiraron cinco ml de 
sangre venosa y se enviaron al laboratorio donde se 
realizó la prueba de inmunoabsorción enzimática de 
enlace enzimático (ELISA), la medición de los autoan-
ticuerpos específicos para la enfermedad celíaca (IgA 
anti-endomisial, IgG y anti-tejido transglutaminasa 
IgA, IgG).
Resultado: hubo una disminución significativa en todos 
los niveles de enzimas después de varios meses de dieta 
sin gluten.
Conclusión: la enfermedad celíaca puede presentar ma-
nifestaciones variables, el seguimiento de la enfermedad 
celíaca. Puede ser importante detectar la adherencia de la 
dieta libre de gluten.
Palabras clave: autoanticuerpos, cambios dietéticos, en-
fermedad celíaca, nivel de enzimas.
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eliac disease (CD) is a health disorder that 
is related to certain genetic events which 
affect the immune system resulting in 
showing such condition. CD is also linked to the effects 
of gluten and prolamins on susceptible humans. The dis-
ease is well-understood for its clinical features according 
to gluten-feeding history plus detecting ACDAs, HLA-
DQ2, DQ8 haplotypes, and enteropathy-based diagnosis. 
Those ACDAs include autoimmune Abs such as AnG and 
AntTG. Gluten and prolamins are present in high amounts 
in wheat and barley. According to some reports, oat was 
noticed to have some prolamin-related CD effects involv-
ing the T-cells in the mucosa, but in general oat is safe. 
The disease occurrence is about 1% of the total biopsy-
examined conditions1. Individuals who have the major his-
tocompatibility complex class II genes plus the allele that 
codes for the human leukocyte antigen (HLA) presented 
by HLA-DQ2 and HLA-DQ82. Environmental effects apply 
some effects in developing CD; however, gluten plays the 
most important role in this process in which gluten stimu-
lates innate immunity that eventually induces inflamma-
tory-based destruction to the GIT mucosa. Removing glu-
ten from diets adds successful improvement to the health 
status of CD patients3,4. This was proven by some studies 
that involved biopsy and tissue-culturing tools5,6. There 
are some methods to diagnose CD, but the main tool is 
the histopathological changes that affect the GIT layers 
such as mucosa. These changes may include atrophy that 
affects villi, hyperplasia that affects crypts, and excessive 
inflammation. The second most important way to detect 
this disease is using ACDAs that work against certain an-
tigenic compounds such as AnG and AntTG. However, 
in certain cases serological tests (STs) may become the 
first choice before doing biopsies using GIT endoscopy. 
In most cases, the STs may face some challenges as they 
have low sensitivity and specificity capacities leading to 
false positive results. In some patients who have different 
GIT health issues may have some serum titers of CD anti-
bodies which may misdiagnose as celiac disease7-9. Some 
developed STs relying on gluten-dependent IgA-class R1-
type reticulin (ARA) and endomysial autoantibody (EMA) 
showed strong results that have accuracy rates of 90%10-
13. For better management of CD, children have to be on 
GDD and to be visited under scheduled time points to 
monitor their health status exposure to a gluten rich diet 
(GRD) after the 2-year exposure to the GDD on the health 
status of those patients.
Aim of study: To determine if serial measurements of ce-
liac disease autoantibodies confirm adherence to gluten 
free diet.
Patients and methods. This cross sectional study was con-
ducted from 1st of Feb. 2015 to 1st of May 2016 and in-
volved all patients that consult the outpatient clinic in Ma-
ternity and Children Hospital in AL-Diwaniah governorate 
complaining  of chronic diarrhea or failure to thrive and 
patients with anemia or pica that were not responding to 
treatment  and patients with short stature without ob-
vious cause in spite of full assessment also any atypical 
symptoms that suggest celiac disease  and their ages be-
tween 9 month to 12 years. Thorough history and physi-
cal examination were performed to all patients with mea-
surement of weight, height and head circumference and 
plotted on chart that suitable for sex and age, all patients 
have GSE and CBC, Blood film and serum iron, IBC, thy-
roid function test, growth hormone. 
123 patients were involved in this study 25 of them were 
excluded (11 of them diagnosed as giardiasis, 7 diagnosed 
as secondary lactase deficiency, 1 patient diagnosed as in-
flammatory bowel disease, 6 families refused  to do more 
investigations) 98 patients  were assessed  for possibil-
ity of celiac disease (sent for anti –tissue trans glutamin-
ase and anti endomysial antibodies and HLA assessment, 
which was performed by a student of master´s degree at 
the College of Medicine University of Al Qadisyah, who 
helped us in doing HLA system. According to the follow-
ing ranges of anticeliac antibodies:   
Normal range      < 12 U\ml
Equivocal range 12-18 U\ml 
Positive result     > 18 U\ml
From each patient five ml of venous blood aspirated and 
sent to the lab in aldiwaniah hospital where Enzyme Link-
ing Immunosorbent assay (ELISA) assay were used for de-
tection and measurement of auto-antibodies specific for 
(anti-endomysial IgA, IgG and anti-tTG IgA,IgG) (Aesku 
Diagnostics Microform ring 2. 55234 Wendelsheim Ger-
many) were  used in this work. 
A buffered solution of the antigen to be tested for is add-
ed to each well of a microtiter plate, where it is given time 
to adhere to the plastic through charge interactions.
·	  A solution of nonreacting protein, such as bovine se-
rum albumin or casein, is added to well (usually 96-
well plates) in order to cover any plastic surface in the 
well which remains uncoated by the antigen.
·	  The primary antibody with an attached (conjugated) 
enzyme is added, which binds specifically to the test 
antigen coating the well.
·	  A substrate for this enzyme is then added. Often, this 
substrate changes color upon reaction with the enzyme.
·	  The higher the concentration of the primary antibody 
present in the serum, the stronger the color change. 
Often, a spectrometer is used to give quantitative val-
ues for color strength. 63 patients were positive for 
both tests: more than 18 unit/ml and HLA DQ2, DQ8. 
Full instructions about the diet of the patient was dis-
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cussed  with their family and mobile phone No. ob-
tained from all patients caregiver and to be checked 
every three months with full history, examination, 
measurements and all patients data were recorded.
After 3 months, 18 patients were excluded (8 lost follow 
up and 10 did not follow strictly the gluten free diet) so 
45 patients were included and the results were obtained.
Statistical analysis.
Discrete variables presented as number and percentage, 
continuous variables presented as mean ±SD (standard 
deviation). Chi square and Fischer´s Exact probability test 
were carried out to examine the association between 
signs and symptoms and level of enzymes. Student t test 
was applied to test the difference between normal and 
abnormal level of enzymes during periods of follow up. 
P-value <0.05 was consider significant. The program was 
used are SPSS version 18.
The results: About 95% of cases were presented and di-
agnosed under the age of three years.
Table 1. Classifications of patients according to the age of 
diagnosis:
%No. of pt.Age in months
73.3339-18
22.21019-36
4.4237-60
00>60
10045Total
Most patients were males figure 3: classifications of pt. 
according to the residence: rural (30), urban (15)
People in rural areas are more affected than those in ur-
ban areas
Table 2: classifications of pt. according to the clinical pre-
sentations: Most patients presented GIT manifestations.
Table 2: classifications of pt. according to the clinical pre-
sentations:
%No.Clinical features
84.538GIT
Non GIT
4.42SS
11.15Pica
Table 3 presents the enzyme level after three months of 
gluten free diet:
Table 3: enzyme level after three months of gluten free diet:
Abnormal enzyme 
level after 3 month
Normal enzyme 
levelNo.
1424GIT symptoms
Non  GIT
20SS
32Pica
Table 4. P-value of enzymes levels after three months of 
gluten free diet there were significant decrease in all en-
zymes levels after  three months of gluten free diet (p-
value <0.05) 
Table 4.  P-value of enzymes levels after three months of glu-
ten free diet
After 3 
month N Mean
Std. 
Deviation
Std. Error 
Mean p-value
IgG tTG
normal 26 9.5000 1.42127 .27873 0.001
abnormal 19 66.4737 39.93379 9.16144
IgA tTG
normal 26 9.6154 1.16883 .22923 0.0042
abnormal 19 57.0000 41.50904 9.52283
IgG EMA
normal 26 9.3077 1.12318 .22027 0.0012
abnormal 19 82.6842 66.00089 15.14164
IgA EMA normal 26 8.7692 1.06987 .20982 0.0031
abnormal 19 73.9474 56.86385 13.04546
After three months of gluten free diet most patients pre-
sented with GIT manifestations have normal enzymes 
while in patients whose presented with non GIT symp-
toms especially those with short stature and pica still have 
high enzymes levels.
Figure 1: classifications of patients according to the sex: 
male (28) female (17)
Figure 2: classifications of pt. according to the residence: 
rural (30), urban (15)
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Table 5: enzyme levels after six months of gluten free diet:
Table 5: enzyme levels after six months of gluten free diet:
Abnormal levelNormal levelNo.
59GIT(13)
Non GIT(6)
11SS
12Pica (3)
Table 6: p_value for enzyme levels after six months of glu-
ten free diet: there were significant decrease in all enzymes 
levels after  six months of gluten free diet (p-value <0.05) 
after six months of gluten free diet only four patients from 
those with GIT symptoms (35patients) still show abnormal 
enzymes levels while three from ten patients with non-GIT 
symptoms have high enzymes level.
Table 6: p_value for enzyme levels after six months of gluten 
free diet:
After 6 
month N Mean
Std. 
Deviation
Std. Error 
Mean p-value
IgA EMA
normal 12 9.1111 .78174 .26058 0.001
abnormal 7 93.1429 48.08128 18.17302
IgA  tTG
normal 12 9.2222 .66667 .22222 0.002
abnormal 7 62.7143 54.34677 20.54115
IgG EMA
normal 12 9.2222 .83333 .27778 0.002
abnormal 7 98.2857 48.58571 18.36367
IgA tTG normal 12 9.0000 .86603 .28868 0.003
abnormal 7 71.0000 45.99638 17.38500
Table 7: enzymes level after nine months:
Table 7: enzymes level after nine months:
Abnormal enzymeNormal enzymeNo.
13GIT (4)
Non  GIT
10SS(1)
10Pica (1)
Table 8: p_value for enzyme levels after nine months of 
gluten free diet: there was significant decrease in all en-
zymes levels after  nine months of gluten free diet (p-value 
<0.05)
After nine months of treatment nearly all patients with 
GIT and non-GIT symptoms, abnormal levels were still 
found in three patients: one with GIT and two with non- 
GIT symptoms. The patient with short stature showed 
good linear increment (about 8cm/year) and had a history 
of very good strict gluten-free diet, about the patient with 
pica, the symptom disappeared after three months of 
treatment but the enzyme levels remained elevated even 
after one year.
Table 8: p_value for enzyme levels after nine months of gluten 
free diet:
N Mean Std. Deviation
Std. Error 
Mean p-value
IgG EMA
Normal 4 9.7500 .50000 .25000 0.001
abnormal 3 88.0000 11.00000 6.35085
IgA EMA
normal 4 9.2500 .95743 .47871 0.02
abnormal 3 87.6667 11.50362 6.64162
IgG tTG
normal 4 9.0000 .81650 .40825 0.004
abnormal 3 62.3333 16.80278 9.70109
IgA tTG normal 4 9.5000 1.29099 .64550 0.005
abnormal 3 66.0000 29.10326 16.80278
Our study shows that most patients may be diagnosed be-
fore the age of three years, in agreement with many stud-
ies done around the world as in Sweden by Anneli et al14, 
who did screening for celiac in children less than 3years 
of age, and stated that the high gluten intake among very 
young Swedish children may increase the prevalence of 
CD. Also male is more affected by CD than female, but 
this disagrees with many studies which explained that CD 
seems to be more frequent in females than males as study 
was done at 2012 in Iran by Mehrdad et al.15 and children 
who live in rural area are more involved by CD than those 
in urban area and this may be explained by the fact that 
children in rural areas have exposed to gluten earlier than 
in urban areas and also there are many studies support 
our finding at 2013 in China by Juanli Yuan et al16. Our 
study proved that about two-third of patients presented 
with GIT manifestations which include diarrhea, vomiting, 
weight loss, steatorrhea, but many patients presented 
non –GIT signs like short stature or pica and there many 
studies support our findings as study by Joseph A Murray 
et al 2004 and this support the thesis which suggest that 
CD is autoimmune disease and can affect many system 
like endocrine and GIT systems and may be present in as-
sociation with other autoimmune diseases17-19.
New guidelines on the diagnosis and treatment of celiac 
disease by the North American Society for Pediatric Gas-
troenterology, Hepatology and Nutrition state that tTG-
IgA testing should be used for follow-up care. Interpret-
ing this test result is straightforward: a celiac pt. on the 
gluten-free diet for at least several months should have a 
negative test. The numerical value of the test is not impor-
tant. Follow-up is very important because most patients 
with celiac disease get better symptomatically with thera-
py, they may not realize the need for follow-up. This view 
may be shared by some of their health care givers. Hence, 
not all patients with celiac disease get regular follow-up 
care. Follow-up is necessary not only to assess symptom-
atic recovery and to monitor complications but also to as-
sist the patient in adhering to the diet. Follow-up care is 
the cornerstone to dietary compliance15. There is good ob-
jective clue that proactive follow up measures can support 
adherence to the gluten-free diet, both in children and 
adults16. Follow-up visits also provide a chance to give the 
patients updated information on new developments. Our 
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study clarified that antibodies measurements in CD pa-
tients are useful in clinical practice. Serial measurements 
of antibodies can allow objective targeting of dietetic 
resources. Our study is unique in that it highlights the 
benefits of measuring serial antibodies levels over several 
months in a routine clinical setting. This result is in agree-
ment with previous work in17 who showed a clear rise in 
antibodies concentration following a gluten challenge in 
patients with controlled CD. Similarly, the finding in this 
study that antibodies levels fall dramatically in the initial 
few months after starting GFD confirms the observations 
of previous studies18,19. And supports serial measurement 
every 3-6-9-12 months until the antibody level has nor-
malized. The published literature on the use of serology 
in monitoring GFD is controversial and contradictory20,21. 
Whilst some studies have not found the rate of fall of an-
tibody concentration to be a dependable marker of strict 
adherence to the GFD22, others have found that normal-
ized markers can be helpful to confirm on-going gluten–
free dietary adherence. Some of the variability in findings 
may be interpreted by the use of the less specific guinea 
pig tTG substrate23-25. Moreover variability between stud-
ies may be caused by the different time courses of chang-
es in serological markers, mucosal biopsy recovery, nutri-
tional deficiencies and identifiable adherence to the GFD. 
The present study indicates how serial antibody measure-
ments are able to provide unique informations with which 
to target dietetic resources. This study has demonstrated 
that complications of CD, particularly, are most commonly 
seen in those with persistently elevated antibodies26,27.
Our study disagree with study done in Department of Pe-
diatrics, Medical University Vienna, by Vécsei at 201317 this 
study demonstrated the limited value of serologic test-
ing in the follow-up of pediatric CD with respect to the 
mucosal status. Only the normalization of EMA indicates 
mucosal healing with acceptable accuracy.  Until more 
dependable tools are available for non-invasive follow-
up, EMA should be used as follow up tool of first choice. 
However, more reliable noninvasive follow-up tools would 
be of great clinical and research usefulness with respect 
to the individualization of the GFD strictness and upcom-
ing studies evaluating the efficacy of new CD treatment 
modalities, respectively28. Study done in Sweden and Sup-
ported by the Swedish Association against Asthma and 
Allergy which compared between tTga and EMA and 
stated that  The human recombinant tTG-based ELISA 
is a sensitive, specific, and reproducible test to support 
the diagnosis and follow-up of childhood celiac disease 
and can be used as an alternative to the EMA test24. Our 
study is also supported by a study in France by Hosking28, 
showed that deamidated gliadin antibodies are strongly 
related with VA and must be considered valuable tools 
in CD follow-up and that multiplex serologic analysis for 
treated CD represents a promising tool for personalized 
patient management28.
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